Skip to main content
Top
Published in: Familial Cancer 2/2010

01-06-2010

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer

Authors: Anna Isinger Ekstrand, Mats Jönsson, Annika Lindblom, Åke Borg, Mef Nilbert

Published in: Familial Cancer | Issue 2/2010

Login to get access

Abstract

The phosphatidylinositol 3-kinases-AKT-mammalian target of rapamycin pathway (PI3K/AKT/mTOR) is central in colorectal tumors. Data on its role in hereditary cancers are, however, scarce and we therefore characterized mutations in PIK3CA and KRAS, and expression of PIK3CA, phosphorylated AKT, and PTEN in colorectal cancers linked to hereditary nonpolyposis colorectal cancer (HNPCC). Sequencing was used to identify mutations in PIK3CA, a real-time PCR-based method to identify KRAS mutations, and immunohistochemical staining was used to evaluate the expression of PIK3CA, phosphorylated AKT and PTEN in 58 HNPCC-associated colorectal cancers. Derangements of at least one of the PI3K/AKT/mTOR components analyzed were found in 51/58 (88%) tumors. Mutations in PIK3CA and KRAS were identified in 14 and 31% of the tumors respectively. Overexpression of PIK3CA and phosphorylated AKT occurred in 59 and 75% and were strongly associated (P = 0.005). Reduced/lost PTEN expression was found in 63% of the tumors. Though HNPCC-associated colorectal cancers show simple genetic profiles with few chromosomal alterations, we demonstrate frequent and repeated targeting of the PI3K/AKT/mTOR pathway, which suggests that therapeutic strategies directed at this pathway are likely to be beneficial also in HNPCC.
Literature
1.
go back to reference Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMed Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMed
2.
go back to reference Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96(8):4240–4245CrossRefPubMed Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96(8):4240–4245CrossRefPubMed
3.
go back to reference Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114(Pt 8):1439–1445PubMed Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114(Pt 8):1439–1445PubMed
4.
go back to reference Miyaki M, Iijima T, Yamaguchi T et al (2007) Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121(7):1627–1630CrossRefPubMed Miyaki M, Iijima T, Yamaguchi T et al (2007) Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121(7):1627–1630CrossRefPubMed
5.
go back to reference Ollikainen M, Gylling A, Puputti M et al (2007) Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121(4):915–920CrossRefPubMed Ollikainen M, Gylling A, Puputti M et al (2007) Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121(4):915–920CrossRefPubMed
6.
go back to reference Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554CrossRefPubMed Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554CrossRefPubMed
7.
go back to reference Velho S, Oliveira C, Ferreira A et al (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41(11):1649–1654CrossRefPubMed Velho S, Oliveira C, Ferreira A et al (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41(11):1649–1654CrossRefPubMed
8.
go back to reference Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851–1857CrossRefPubMed Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851–1857CrossRefPubMed
9.
go back to reference Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1):113–130CrossRefPubMed Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1):113–130CrossRefPubMed
10.
go back to reference Allen BA, Terdiman JP (2003) Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol 17(2):237–258CrossRefPubMed Allen BA, Terdiman JP (2003) Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol 17(2):237–258CrossRefPubMed
11.
go back to reference Peltomaki P, Lothe RA, Aaltonen LA et al (1993) Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53(24):5853–5855PubMed Peltomaki P, Lothe RA, Aaltonen LA et al (1993) Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53(24):5853–5855PubMed
12.
go back to reference Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20(4–5):269–276PubMed Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20(4–5):269–276PubMed
13.
go back to reference Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116(6):1453–1456CrossRefPubMed Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116(6):1453–1456CrossRefPubMed
14.
go back to reference Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10(1):13–27CrossRefPubMed Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10(1):13–27CrossRefPubMed
15.
go back to reference Isinger A, Bhat M, Borg A et al (2006) CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum. BMC Cancer 6:64CrossRefPubMed Isinger A, Bhat M, Borg A et al (2006) CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum. BMC Cancer 6:64CrossRefPubMed
16.
go back to reference Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554–2559CrossRefPubMed Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554–2559CrossRefPubMed
17.
go back to reference Kato S, Iida S, Higuchi T et al (2007) PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121(8):1771–1778CrossRefPubMed Kato S, Iida S, Higuchi T et al (2007) PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121(8):1771–1778CrossRefPubMed
18.
go back to reference Parsons DW, Wang TL, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792CrossRefPubMed Parsons DW, Wang TL, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792CrossRefPubMed
19.
go back to reference Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65(23):10669–10673CrossRefPubMed Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65(23):10669–10673CrossRefPubMed
20.
go back to reference Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510CrossRefPubMed Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510CrossRefPubMed
21.
go back to reference Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562–4567CrossRefPubMed Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562–4567CrossRefPubMed
22.
go back to reference Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573CrossRefPubMed Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573CrossRefPubMed
23.
go back to reference Fenic I, Steger K, Gruber C et al (2007) Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18(1):253–259PubMed Fenic I, Steger K, Gruber C et al (2007) Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18(1):253–259PubMed
24.
go back to reference Wang Y, Kristensen GB, Helland A et al (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124(3):392–401CrossRefPubMed Wang Y, Kristensen GB, Helland A et al (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124(3):392–401CrossRefPubMed
25.
go back to reference Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103(5):1475–1479CrossRefPubMed Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103(5):1475–1479CrossRefPubMed
26.
go back to reference Isakoff SJ, Engelman JA, Irie HY et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992–11000CrossRefPubMed Isakoff SJ, Engelman JA, Irie HY et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992–11000CrossRefPubMed
27.
go back to reference Zhao JJ, Liu Z, Wang L et al (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102(51):18443–18448CrossRefPubMed Zhao JJ, Liu Z, Wang L et al (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102(51):18443–18448CrossRefPubMed
28.
go back to reference Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10(6):534–541PubMed Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10(6):534–541PubMed
Metadata
Title
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer
Authors
Anna Isinger Ekstrand
Mats Jönsson
Annika Lindblom
Åke Borg
Mef Nilbert
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9293-1

Other articles of this Issue 2/2010

Familial Cancer 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine